Mark Breidenbach
Stock Analyst at Oppenheimer
(1.64)
# 3,449
Out of 5,126 analysts
48
Total ratings
30.91%
Success rate
0.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Maintains: Outperform | $9 → $7 | $1.69 | +314.20% | 6 | Aug 1, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $16.85 | +78.04% | 4 | Sep 4, 2024 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $13.48 | +604.75% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $4.93 | +407.10% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.32 | +3,024.02% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $13.96 | +1,619.20% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $2.98 | +5,269.13% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.67 | +319.16% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.57 | +1,938.22% | 2 | Mar 10, 2023 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $25 → $15 | $2.53 | +492.89% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $0.79 | +1,238,467.07% | 2 | May 12, 2020 |
Allogene Therapeutics
Aug 1, 2025
Maintains: Outperform
Price Target: $9 → $7
Current: $1.69
Upside: +314.20%
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $16.85
Upside: +78.04%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $13.48
Upside: +604.75%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $4.93
Upside: +407.10%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.32
Upside: +3,024.02%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $13.96
Upside: +1,619.20%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $2.98
Upside: +5,269.13%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.67
Upside: +319.16%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.57
Upside: +1,938.22%
Iovance Biotherapeutics
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $2.53
Upside: +492.89%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $0.79
Upside: +1,238,467.07%